Development
Cytokinetics, Incorporated
CYTK
$36.16
-$0.42-1.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -14.56% | -84.97% | -55.95% | 301.83% | -96.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.56% | -84.97% | -99.03% | 301.83% | -96.48% |
| Cost of Revenue | 13.27% | 31.56% | 45.63% | 72.90% | 72.46% |
| Gross Profit | -14.02% | -36.43% | -358.55% | -67.03% | -703.71% |
| SG&A Expenses | -18.26% | -16.82% | -7.01% | 50.18% | 59.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.08% | 10.53% | 23.11% | 63.39% | 66.86% |
| Operating Income | -0.31% | -12.75% | -1,022.39% | -59.87% | -485.28% |
| Income Before Tax | 0.35% | 9.06% | -549.03% | -46.78% | -349.39% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.35% | 9.06% | -549.03% | -46.78% | -349.39% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.35% | 9.06% | -549.03% | -46.78% | -349.39% |
| EBIT | -0.31% | -12.75% | -1,022.39% | -59.87% | -485.28% |
| EBITDA | 3.42% | -12.50% | -1,169.61% | -60.26% | -497.86% |
| EPS Basic | 4.76% | 11.25% | -481.06% | -31.10% | -299.06% |
| Normalized Basic EPS | 4.76% | -5.20% | -481.04% | -35.18% | -299.16% |
| EPS Diluted | 4.76% | 11.25% | -481.06% | -31.10% | -298.08% |
| Normalized Diluted EPS | 4.76% | -5.20% | -481.04% | -35.18% | -299.16% |
| Average Basic Shares Outstanding | 4.63% | 2.47% | 11.69% | 11.96% | 12.60% |
| Average Diluted Shares Outstanding | 4.63% | 2.47% | 11.69% | 11.96% | 12.60% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |